Pharmaceutical intermediates
Daridorexant Hydrochloride Intermediates
4 pharmaceutical intermediates for Daridorexant Hydrochloride. Indication: Sleep onset and sleep disorders.
About Daridorexant Hydrochloride
- Originator
- Actelion Pharmaceuticals Ltd
- Indication
- Sleep onset and sleep disorders
- Approved Date
- 04/07/2022
- NCE Patent
- 04/07/2027
- DS/DP
- 06/12/2033
Available intermediates
4 intermediates currently listed for Daridorexant Hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Chloro-3-Methylbenzene-1,2- diaMine hydrochloride | 1087743-89-2 | / | / |
| 2-Methyl-L-proline Methyl ester hydrochloride | 220060-08-2 | / | / |
| (S)-2-Methylpyrrolidine-2- carboxylic acid hydrochloride | 1508261-86-6 | / | / |
| 5-methoxy-2-(2H-1,2,3-triazol-2- yl)benzoic acid | 1293284-55-5 | / | / |
Building toward Daridorexant Hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →